Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

iBio Announces Preclinical Data In Which An Engineered Amylin Receptor Agonist Antibody Reduced Acute Food Intake In A Mouse Model Of Obesity By 60%, Equivalent To The Reduction In Food Intake From A Clinically Advanced Dual Amylin And Calcitonin Receptor Agonist Peptide (67%).

Author: Benzinga Newsdesk | June 24, 2025 07:03am
  • Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist
  • Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases

Posted In: IBIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist